Dergiler / Retina-Vitreus / 2018 / Cilt: 27 - Sayı: 1

Central Retinal Vein Occlusion Associated With Varenicline

Vareniklinle İlişkili Santral Retinal Ven Tıkanıklığı

Sayfa
86–89
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

This case report shows a varenicline (Champix, Pfi zer, Mumbai, India)-associated acute thrombotic CRVO in a patient without previous history of systemic infl ammation or vascular occlusive disease.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Retinal venous occlusive disease is the second most common retinal vascular disorder following diabetic retinopathy.The exact pat- hogenesis and risk factors of RVO in younger patients—most of whom are otherwise healthy are still poorly understood.
📊
Temel Bulgular & Veri:Retinal venous occlusive disease is the second most common retinal vascular disorder following diabetic retinopathy.The exact pat- hogenesis and risk factors of RVO in younger patients—most of whom are otherwise healthy are still poorly understood.
💡
Sonuç & Katkı:This case report shows a varenicline (Champix, Pfi zer, Mumbai, India)-associated acute thrombotic CRVO in a patient without previous history of systemic infl ammation or vascular occlusive disease.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Retinal venous occlusive disease is the second most common retinal vascular disorder following diabetic retinopathy.The exact pat- hogenesis and risk factors of RVO in younger patients—most of whom are otherwise healthy are still poorly understood. This case report shows a varenicline (Champix, Pfi zer, Mumbai, India)-associated acute thrombotic CRVO in a patient without previous history of systemic infl ammation or vascular occlusive disease.

Abstract

Retinal ven tıkanıklığı,diyabetik retinopatiden sonra en yaygın retinal vasküler hastalıktır. Çoğu sağlıklı olan genç hastalarda retinal ven tıkanıklığının patogenezi ve risk faktörleri henüz tam olarak anlaşılamamıştır.Bu olgu sunumu, daha önce sistemik infl amasyon veya vasküler tıkayıcı hastalık öyküsü olmayan bir hastada vareniklinle(Champix, Pfi zer, Mumbai, India ) ilişkili akut trombotik SRVO’yu göstermektedir.

🔖

Bu Makaleye Atıf Yap

EROĞLU, A. (2018). Central Retinal Vein Occlusion Associated With Varenicline. Retina-Vitreus, Cilt: 27 - Sayı: 1, 86–89. https://ajindex.com/articles/304823

Kaynakça (8)

  1. Yanoff M,Duker JS.Ophthalmology Part 6.19, Elsevier Press 2014, ed 4, pp 526-534. The Eye Disease Case-Control Study Group. Risk factors for cen- tral retinal vein occlusion. Arch Ophthalmol 1996;114:545–54.
  2. Fong AC, Schatz H. Central retinal vein occlusion in young adults. Surv Ophthalmol 1993;37:393–417. Gutman FA. Evaluation of a patient with central retinal vein occlu- sion. Ophthalmology 1983;90:481–3.
  3. Bhagat N, Goldberg MF, et al.: Central retinal vein occlusion: re- view of management. Eur J Ophthalmol 1999, 9:165-180. 6. Kanski JJ,Bowling B.Part 13. Elsevier,Printed in China,Press 2016,ed 8, pp 538-549.
  4. Kirwan JF, Tsaloumas MD, Vinall H,et al. Sex hormone prepara- tions and retinal vein occlusion. Eye 1997;11:53. Yong KC, Kah TA, Ghee YT,et al. Branch retinal vein occlusion associated with quetiapine fumarate. BMC Ophthalmol. 2011 Aug 25;11:24. K.B. Mihalak, F.I. Carroll, C.W. Luetje, Varenicline is a partial ag- onist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors, Mol. Pharmacol. 70 (2006) 801–805.
  5. M. Nakamura, A. Oshima, Y. Fujimoto,et al.Effi cacy and tolera- bility of varenicline, an alpha4beta2 nicotinic acetylcholine recep- tor partial agonist, in a 12-week, randomized, placebo-controlled, dose response study with 40-week follow-up for smoking cessa- tion in Japanese smokers, Clin. Ther. 29 (2007) 1040–1056.
  6. Rigotti NA, Pipe AL, Benowitz NL, et al.Effi cacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: A randomized trial. Circulation. 2010;121:221-229.
  7. Svanstrom H, Pasternak B, Hviid A. Use of varenicline for smok- ing cessation and risk of serious cardiovascular events: nationwide cohort study. BMJ. 2012;345:e7176. Koga M, Kanaoka Y, Ohkido Y, et al.Biochemical and Biophysical Research Communications 455 (2014) 194 -197. A. Kalayci, A. Eren, G. Kocabay, et al. Varenicline induced coro- nary thrombosis, Ann. Pharmacother. 47 (2013) 1727–1729. Food and Drug Administration. FDA drug safety communication: Safety review update of Chantix (varenicline) and risk of cardi- ovascular adverse events. http://www.fda.gov/Drugs/DrugSafety/ ucm330367.htm. Accessed October 3, 2013. Chantix varenicline tablets [product information]. http://www.ac- cessdata.fda.gov/drugsatfda_docs/label/2009/021928s012s013lbl. pdf Accessed October 3, 2013.
  8. Naranjo CA, Busto U, Sellers EM, et al. Green WR. Histopathologic studies of hypotensive retinopathy, branch vein occlusion, and central retinal vein oc